The need for an artificial oxygen carrier for disasters and pandemics, including COVID-19

Transfusion

Volumn 60, Issue 12, 2020, Pages 3039-3045

  Weiskopf, Richard B ^a   Glassberg, Elon ^b,c   Guinn, Nicole R ^d   James, Michael F M ^e   Ness, Paul M ^f   Pusateri, Anthony E ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL CORPS   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMERIZED HEMOGLOBIN; HEMOGLOBIN; OXYGEN;

ANEMIA; CLINICAL FEATURE; CORONAVIRUS DISEASE 2019; DISASTER; DISEASE SEVERITY; DISEASE TRANSMISSION; ERYTHROCYTE TRANSFUSION; HUMAN; MORTALITY RATE; NOTE; PANDEMIC; PATIENT RISK; RISK FACTOR; SURVIVAL RATE; BLOOD TRANSFUSION;

BLOOD TRANSFUSION; COVID-19; DISASTERS; HEMOGLOBINS; HUMANS; OXYGEN; PANDEMICS; SARS-COV-2;

EID: 85096714800     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.16122     Document Type: Note

References (69)

1. American Red Cross. American Red Cross faces a severe blood shortage as coronavirus outbreak threatens availability of nationʼs supply. 2020.
2. Pagano MB, Hess JR, Tsang HC, et al. Prepare to adapt: Blood supply and transfusion support during the first 2 weeks of the 2019 Novel Coronavirus (COVID-19) pandemic affecting Washington State. Transfusion. 2020;60:908–911.
3. Tsubokura M, Nakada H, Matsumura T, et al. The impact of H1N1 influenza A virus pandemic on the blood donations in Hyogo Prefecture, Japan. Transfusion. 2010;50:1803–1805.
4. Shan H, Zhang P. Viral attacks on the blood supply: the impact of severe acute respiratory syndrome in Beijing. Transfusion. 2004;44:467–469.
5. Chang L, Zhao L, Gong H, Wang L, Wang L. Severe acute respiratory syndrome coronavirus 2 RNA detected in blood donations. Emerg Infect Dis. 2020;26:1631–1633. https://doi.org/10.3201/eid2607.200839.
6. Linden JV, Davey RJ, Burch JW. The September 11, 2001 disaster and the New York blood supply. Transfusion. 2002;42:1385–1387.
7. Jones RL. September eleventh. Vox Sang. 2002;83(suppl 1):363–365.
8. Glynn SA, Busch MP, Schreiber GB, et al. Effect of a national disaster on blood supply and safety: the September 11 experience. JAMA. 2003;289:2246–2253.
9. Simonetti A, Ezzeldin H, Walderhaug M, Anderson SA, Forshee RA. An inter-regional US blood supply simulation model to evaluate blood availability to support planning for emergency preparedness and medical countermeasures. Disaster Med Public Health Prep. 2018;12:201–210.
10. Schmidt PJ. Blood and disaster--supply and demand. N Engl J Med. 2002;346:617–620.
11. Lozada MJ, Cai S, Li M, Davidson SL, Nix J, Ramsey G. The Las Vegas mass shooting: An analysis of blood component administration and blood bank donations. J Trauma Acute Care Surg. 2019;86:128–133.
12. Gevirtz C. Blood and disaster. N Engl J Med. 2002;347:68–69; author reply −9.
13. Pusateri AE, Given MB, Macdonald VW, Homer MJ. Comprehensive US government program for dried plasma development. Transfusion. 2016;56(suppl 1):S16–S23.
14. Pusateri AE, Homer MJ, Rasmussen TE, Kupferer KR, Hoots WK. The interagency strategic plan for research and development of blood products and related technologies for trauma care and emergency preparedness 2015-2020. Am J Disaster Med. 2018;13:181–194.
15. Gale RP. Immediate medical consequences of nuclear accidents. Lessons from Chernobyl. JAMA. 1987;258:625–628.
16. Anspaugh LR, Catlin RJ, Goldman M. The global impact of the Chernobyl reactor accident. Science. 1988;242:1513–1519.
17. Young RW. Chernobyl in retrospect. Pharmacol Ther. 1988;39:27–32.
18. United Nations Scientific Committee on the Effects of Atomic Radiation. The Chernobyl accident. [cited 2020 Aug 26]. Available from: https://wwwunscearorg/unscear/en/chernobylhtml.
19. Committee on Medical Preparedness for a Terrorist Nuclear Event of the Institute of Medicine of the National Academies. Assessing medical preparedness to respond to a terrorist nuclear event. workshop report. Washington, DC: The National Academies Press, 2009.
20. National Security Staff Interagency Policy Coordination Subcommittee for Preparedness & Response to Radiological and Nuclear Threats. Planning Guidance for Response to a Nuclear Detonation, 2nd ed. 2010.
21. U.S. Department of Health and Human Services. Medical planning and response manual for a nuclear detonation incident: A practical guide. 2011.
22. Klein HG, Hrouda JC, Epstein JS. Crisis in the sustainability of the U.S. blood system. N Engl J Med. 2017;377:1485–1488.
23. Mulcahy AW, Kapinos KA, Briscombe B, et al. Toward a sustainable blood supply in the United States. An analysis of the current system and alternatives for the future. Santa Monica, CA: RAND Corporation, 2016.
24. Pusateri AE, Butler F, Shackelford SA, et al. The need for dried plasma — a national issue. Transfusion. 2019;59:1587–1592.
25. Cannan R, Redish J. The large-scale production of crystalline human hemoglobin: with preliminary observations on the effect of its injection in man. In: Mudd S, Thalhimer W, editors. Blood substitutes and blood transfusion. Springfield: Thomas, 1942.
26. Amberson W, Jennings J, Rhode C. Clinical experience with hemoglobin-saline solutions. J Appl Physiol. 1949;1:469–489.
27. Clark L, Gollan R. Survival of mammals breathing organic liquids equilibrated with oxygen a atmospheric pressure. Science. 1966;152:1755–1756.
28. Aach RD, Szmuness W, Mosley JW, et al. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med. 1981;304:989–994.
29. Hollinger FB, Alter HJ, Holland PV, Aach RD. Non-A, non-B posttransfusion hepatitis in the United States. In: Gerety RJ, editor. Non-A, non-B hepatitis. New York, NY: Academic Press, 1981; p. 49–70.
30. Hollinger F, Mosley J, Szmuness W, et al. Non-A, Non-B hepatitis following blood transfusion: risk factors associated with donor characteristics. In: Szmuness W, Alter H, Maynard J, editors. Viral Hepatitis 1981 International Symposium. Philadelphia: The Franklin Institute Press, 1982; p. 361–376.
31. Curran JW, Lawrence DN, Jaffe H, et al. Acquired immunodeficiency syndrome (AIDS) associated with transfusions. N Engl J Med. 1984;310:69–75.
32. Busch M, Glynn S, Stramer S, et al. A new strategy for estimating risks of transfusion-transmittted viral infections based on rates of detection of recently infected donors. Transfusion. 2005;45:254–264.
33. Silverman TA, Weiskopf RB, for the Planning Committee and Speakers. Hemoglobin based oxygen carriers: Current status and future directions. Anesthesiology. 2009;111:946–963.
34. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: A meta-analysis. JAMA. 2008;299:2304–2312.
35. Levien LJ, Hodgson RE, James MFM. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA. 2008;300:1295.
36. Keipert PE. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA. 2008;300:1295–1296.
37. Lewis RJ, Fost N. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA. 2008;300:1296.
38. Shander A, Thompson G. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA. 2008;300:1296–1297.
39. Sauaia A, Moore EE, Banerjee A. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA. 2008;300:1297.
40. Mackenzie C, Dube GP, Pitman A, Zafirelis M. Users guide to pitfalls and lessons learned about HBOC-201 during clinical trials, expanded access, and clinical use in 1,701 patients. Shock. 2019;52(1S suppl 1):92–99.
41. Food and Drug Administration. 21 CFR Parts 606, 610, and 640. Biological products; blood and blood derivatives; implementation of efficacy review. 1985:50FR52602-723.
42. Weiskopf RB. The efficacy and safety of liquid stored blood and storage duration: a confused subject; are patients confused? Anesth Analg. 2014;119:224–229.
43. Hill-Pryor C, Pusateri AE, Weiskopf RB. Hemoglobin-based oxygen carriers (HBOC)-what the next generation holds: When red blood cells are not an option. Shock. 2019;52:4–6.
44. Weiskopf RB, Beliaev AM, Shander A, et al. Addressing the unmet need of life-threatening anemia with hemoglobin-based oxygen carriers. Transfusion. 2017;57:207–214.
45. Weiskopf RB, Kramer JH, Viele M, et al. Acute severe isovolemic anemia impairs cognitive function and memory in humans. Anesthesiology. 2000;92:1646–1652.
46. Weiskopf RB, Feiner J, Hopf HW, et al. Oxygen reverses deficits of cognitive function and memory and increased heart rate induced by acute severe isovolemic anemia. Anesthesiology. 2002;96:871–877.
47. Weiskopf RB, Feiner J, Hopf H, et al. Fresh blood and aged stored blood are equally efficacious in immediately reversing anemia-induced brain oxygenation deficits in humans. Anesthesiology. 2006;104:911–920.
48. Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA. 1998;279:217–221.
49. Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion. 2002;42:812–818.
50. Shander A, Javidroozi M, Naqvi S, et al. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion (CME). Transfusion. 2014;54:2688–2695.
51. Beliaev AM, Marshall RJ, Gordon M, Smith W, Windsor JA. Clinical benefits and cost-effectiveness of allogeneic red-blood-cell transfusion in severe symptomatic anaemia. Vox Sang. 2012;103:18–24.
52. Jahr JS, Mackenzie C, Pearce LB, Pitman A, Greenburg AG. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma. 2008;64:1484–1497.
53. Food and Drug Administration. 21 CFR Parts 312 and 316: Expanded access to investigational drugs for treatment use. 2009:74FR40900.
54. DHHS US, FDA, CDER, CBER. Guidance for Industry: Individual Patient Expanded Access Applications: Form FDA 392. 2017.
55. Guinn NR, Cooter ML, Weiskopf R. Lower hemoglobin concentration decreases time to death in severely anemic patients for whom blood transfusion is not an option. J Trauma Acute Care Surg. 2020;88:803–808.
56. Beliaev AM, Marshall RJ, Smith W, Windsor JA. Mortality risk stratification in severely anaemic Jehovahʼs Witness patients. Intern Med J. 2012;42:e1–e3.
57. Guinn NR, Cooter ML, Villalpando C, Weiskopf RB. Severe anemia associated with increased risk of death and myocardial ischemia in patients declining blood transfusion. Transfusion. 2018;58:2290–2296.
58. Zafirelis Z. Personal communication 2020.
59. Levien LJ. South Africa: Clinical experience with Hemopure. ISBT Sci Ser. 2006;1:167–173.
60. Potgieter H, James M. The use of Hemopure(R) at Groote Schuur Hospital, Cape Town: 4 cases studies. South Afr J Anaesth Analg. 2009;15:13–15.
61. Mer M, Hodgson E, Wallis L, et al. Hemoglobin glutamer-250 (bovine) in South Africa: Consensus usage guidelines from clinician experts who have treated patients. Transfusion. 2016;56:2631–2636.
62. Zumberg M, Gorlin J, Griffiths EA, et al. A case study of 10 patients administered HBOC-201 in high doses over a prolonged period: Outcomes during severe anemia when transfusion is not an option. Transfusion. 2020;60:932–939.
63. Carlsen E, Comroe JH Jr. The rate of uptake of carbon monoxide and of nitric oxide by normal human erythrocytes and experimentally produced spherocytes. J Gen Physiol. 1958;42:83–107.
64. Viele MK, Weiskopf RB, Fisher D. Recombinant human hemoglobin does not affect renal function in humans: analysis of safety and pharmacokinetics. Anesthesiology. 1997;86:848–858.
65. Mollan TL, Alayash AI. Redox reactions of hemoglobin: mechanisms of toxicity and control. Antioxid Redox Signal. 2013;18:2251–2253.
66. Meliga E, Vranckx P, Regar E, Kint PP, Duncker DJ, Serruys PW. Proof-of-concept trial to evaluate haemoglobin based oxygen therapeutics in elective percutaneous coronary revascularisation. Rationale, protocol design and haemodynamic results. EuroIntervention. 2008;4:99–107.
67. Serruys PW, Vranckx P, Slagboom T, et al. Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 in patients undergoing PCI for CAD. EuroIntervention. 2008;3:600–609.
68. Briefing book for the 14 December 2006 Blood Products Advisory Committee (BPAC) meeting. 2006. Available from: https://wayback.archive-it.org/7993/20170405060614/https://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4270B1-11.pdf. Accessed on 16 March 2020.
69. Jones DG, Nantais J, Rezende-Neto JB, Yazdani S, Vegas P, Rizoli S. Crystalloid resuscitation in trauma patients: deleterious effect of 5L or more in the first 24h. BMC Surg. 2018;18:93.